A company (I think they are still private) called SCYNEXIS has a webcast http://noble.mediasite.com/mediasite/SilverlightPlayer/Default.aspx?peid=0e04597426a946268a52b0710e9c29501d They have an HCV mechanism I never heard http://www.scynexis.com/pipeline/scy-635-hcv-clinical-candidate/ Core SCY-635 Facts Inhibits host cyclophilin A, a mechanism shown to completely suppress viral replication in vitro Maybe they are preparing their IPO while the market is ripe :-)